Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Metabolic & Neurodegenerative Disease Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for NPY2R drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Gene Delivery | NPY2R Lentivirus Premade Particles Full-length ORF with GFP/mCherry, High titer (>10^8 TU/ml), Puromycin selection. Sequence Verified. |
View NPY2R Products |
| Antigen | NPY2R Extracellular Domain (ECD) Protein HEK293 Expressed, Theoretical MW verified, High Purity (>90%), Endotoxin <1EU/ug. |
View NPY2R Products |
| Validator | NPY2R siRNA Set (3 unique sequences) For knockdown verification and specificity control. Sequence Verified. |
View NPY2R Products |
| Ligand Control | NPY (Neuropeptide Y) Recombinant Protein Native sequence, High purity (>95%), endotoxin controlled for functional assays. |
View NPY Products |
| Related Target: NPY1R | NPY1R (Y1 Receptor) Critical for selectivity screening vs. Y2; Gi-coupled comparator for cross-reactivity assays. |
View NPY1R Products |
| Related Target: NPY5R | NPY5R (Y5 Receptor) Metabolic pathway partner; essential for subfamily off-target liability assessment. |
View NPY5R Products |
Critical Assay Challenges & Technical Specifications
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| GPCR Conformation Integrity (NPY2R requires native membrane environment for ligand binding) | Lentivirus-Mediated Stable Cell Lines HEK293T packaging ensures native glycosylation and membrane insertion; compatible with Promiscuous Gα16 for Calcium flux assays. |
| NPY Receptor Subfamily Selectivity (Y1/Y2/Y4/Y5 cross-reactivity liability) | Ortholog Panel Availability Human/Mouse/Cyno NPY2R sequences available with >95% homology coverage; strict mass spec identity confirmation. |
| Peptide Ligand Stability (NPY/PYY prone to degradation) | Endotoxin-Controlled Production <1 EU/ug specification prevents macrophage activation artifacts in functional assays; serum-free compatible. |
| False Positive Elimination (Off-target GPCR activation) | Validated siRNA Controls Gene-specific knockdown validation set included for assay specificity verification. |
Live NPY2R R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for NPY2R therapeutics is intensifying, with major players shifting focus from traditional small molecule antagonists to peptide-based modulators and allosteric regulators. As first-generation NPY receptor ligands faced subfamily selectivity challenges, the next wave of R&D is targeting biased signaling pathways (β-arrestin vs. G-protein selective) to dissociate metabolic efficacy from central nervous system side effects. Emerging indications in neurodegeneration (hippocampal neurogenesis) and vascular remodeling are expanding the addressable market beyond obesity.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Peptide Analogs | Novo Nordisk, Eli Lilly (exploratory) | Obesity, Metabolic Syndrome | Internalization/Recycling Assays (Need stable cell lines with high surface expression) |
| Small Molecule Antagonists | Bristol Myers Squibb, Biotech startups | Neurodegeneration, Anxiety | Selectivity Panel (Need Y1/Y4/Y5 ortholog proteins for cross-screening) |
| Biased Modulators | Academic consortia, CRO partnerships | Vascular Disease | Pathway-Specific Reporting (Need β-arrestin vs. cAMP assay compatibility) |